Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viveta
- Development stage
- Phase 4
- Lead developer
- United Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Viveta is a topical anesthetic cream containing a combination of lidocaine (7% w/w) and tetracaine (7% w/w). Manufactured by Ajanta Pharma, it is used to provide local anesthesia for minor dermatological and surgical procedures, including laser treatments, tattoo removal, dermal filler injections, and skin biopsies. The mechanism of action involves the reversible blockade of voltage-gated sodium channels in nerve fibers, which inhibits the ionic fluxes required for the initiation and conduction of pain impulses. Following topical application, the cream typically induces numbness within the treated area that lasts for approximately one to two hours.
- Brand names
- Viveta
- Other names
- Viveta Cream
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Viveta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viveta.